Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes

Epilepsy and Behavior

Volumn 57, Issue , 2016, Pages 105-110

  Clark, Annie M ^a   Pellock, John M ^b   Holmay, Mary ^a   Anders, Bob ^a   Cloyd, James ^c  

^a Upsher Smith Laboratories Inc   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antiepileptic drug; Bioequivalence; Epilepsy; Feeding tubes; Qudexy XR; Sprinkle

Indexed keywords

DEIONIZED WATER; TOPIRAMATE; ANTICONVULSIVE AGENT; DELAYED RELEASE FORMULATION; FRUCTOSE; MICROCAPSULE;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSGEUSIA; EXTENDED RELEASE CAPSULE; FEMALE; FOOD; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; IN VITRO STUDY; INSOMNIA; INTACT CAPSULE; JEJUNOSTOMY TUBE; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOFT FOOD; SPRINKLE DELIVERY; SPRINKLED CAPSULE; STOMACH TUBE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; DELAYED RELEASE FORMULATION; ENTERIC FEEDING; MICROCAPSULE; MIDDLE AGED; THERAPEUTIC EQUIVALENCE;

ADULT; ANTICONVULSANTS; AREA UNDER CURVE; CAPSULES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; ENTERAL NUTRITION; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 84959354839     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2016.01.034     Document Type: Article

References (20)

1. Lee S.K. Old versus new: why do we need new antiepileptic drugs?. J Epilepsy Res 2014, 4:39-44.
2. Benbadis S., Stefan H., Morita D., Abou-Khalil B., Hogan R.E. Pharmacologic decision-making in the treatment of focal epilepsy-a critical comparison of antiepileptic drugs. US Neurol 2014, 10:92-103.
3. Institute of Medicine (U.S.), Committee on the Public Health Dimensions of the Epilepsies Introduction. Epilepsy across the spectrum: promoting health and understanding 2012, 26. National Academies Press, Washington, D.C. M.J. England, C.T. Liverman, A.M. Schultz, L.M. Strawbridge (Eds.).
4. Leppik I.E., Birnbaum A.K. Epilepsy in the elderly. Ann N Y Acad Sci 2010, 1184:208-224.
5. Pellock J.M., Morton L.D. Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Disabil Res Rev 2000, 6:309-323.
6. Stefan H. Improving the effectiveness of drugs in epilepsy through concordance. Adv Clin Neurosci Rehabil 2009, 8:15-18.
7. Williams N.T. Medication administration through enteral feeding tubes. Am J Health Syst Pharm 2008, 65:2347-2357.
8. Hosain S.A., La Vega-Talbott M., Solomon G.E. Ketogenic diet in pediatric epilepsy patients with gastrostomy feeding. Pediatr Neurol 2005, 32:81-83.
9. Clark A.M., Halvorsen M.B., Braun T.L., Johnson K.M., Cloyd J.C. USL255 extended-release topiramate: dose-proportional pharmacokinetics and tolerability in healthy volunteers. Epilepsia 2014, 55:1069-1076.
10. Bialer M., Shekh-Ahmad T., Braun T.L., Halvorsen M.B. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Epilepsia 2013, 54:1444-1452.
11. Chung S.S., Fakhoury T.A., Hogan R.E., Nagaraddi V.N., Blatt I., Lawson B., et al. Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study. Epilepsia 2014, 55:1077-1087.
12. Hogan R.E., Blatt I., Lawson B., Nagaraddi V., Fakhoury T.A., Anders B., et al. Efficacy of once-daily extended-release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy Behav 2014, 41:136-139.
13. Qudexy® XR. (Topiramate) extended-release capsules. Prescribing information 2015, Upsher-Smith Laboratories, Inc., Maple Grove, MN, US.
14. Lambrecht L.J., Shekh-Ahmad T., Todd W.M., Halvorsen M.B., Bialer M. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. Epilepsia 2011, 52:1877-1883.
15. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker, New York, NY. 2nd ed.
16. Eliot L., Butler J., Devane J., Loewen G. Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation. Clin Ther 2002, 24:260-268.
17. Chung S. USL255 extended-release topiramate for the treatment of epilepsy. Expert Rev Neurother 2014, 14:1127-1137.
18. Sura L., Madhavan A., Carnaby G., Crary M.A. Dysphagia in the elderly: management and nutritional considerations. Clin Interv Aging 2012, 7:287-298.
19. Jones-Saete C., Kriel R.L., Cloyd J.C. External leakage from feeding gastrostomies in patients receiving valproate sprinkle. Epilepsia 1992, 33:692-695.
20. Riss J.R., Kriel R.L., Kammer N.M., Judge M.K., Montgomery M.J. Administration of Carbatrol to children with feeding tubes. Pediatr Neurol 2002, 27:193-195.